MedPath

Sulfate ion

Generic Name
Sulfate ion
Drug Type
Small Molecule
Chemical Formula
O4S
CAS Number
14808-79-8
Unique Ingredient Identifier
7IS9N8KPMG

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Aug 6, 2025

The Sulfate Ion (DB14546): A Comprehensive Monograph on its Physicochemical, Biological, Pharmacological, and Environmental Significance

Executive Summary

The sulfate ion (DrugBank ID: DB14546, CAS: 14808-79-8), a simple divalent anion, represents a molecule of profound and multifaceted significance. While it possesses direct pharmacological activity as a medication, specifically as an osmotic laxative, this application constitutes only a narrow facet of its overall importance. This report provides a comprehensive, multi-domain analysis of the sulfate ion, revealing its identity as a fundamental biological component, a critical tool in pharmaceutical sciences, a versatile industrial chemical, and a major environmental agent. Biologically, sulfate is the fourth most abundant anion in human plasma, essential for detoxification, metabolic regulation, and the structural integrity of tissues. Its role in the sulfonation of hormones, neurotransmitters, and xenobiotics is a cornerstone of human physiology, and its availability is critical for proper fetal development. In pharmacology, beyond its use as a laxative, sulfate's primary contribution is as a counter-ion. By forming salts with basic active pharmaceutical ingredients (APIs), it enhances their solubility, stability, and bioavailability, making many essential drugs—from antibiotics to opioids—viable for clinical use. Industrially, sulfate compounds are cornerstones of agriculture, construction, and manufacturing. Environmentally, sulfate presents a complex paradox: it is the principal agent of acid rain, causing widespread ecological damage, yet as an atmospheric aerosol, it exerts a significant cooling effect on the global climate. This report synthesizes these disparate roles, demonstrating that the function and impact of the sulfate ion are entirely defined by its chemical, biological, and environmental context. Understanding this context is essential for clinicians, scientists, and policymakers ali

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/08
Not Applicable
Recruiting
Syed Hamza Mufarrih
2025/03/19
Phase 3
Not yet recruiting
2024/12/19
Not Applicable
Recruiting
Arooj Khan
2024/07/25
N/A
Not yet recruiting
2024/04/16
Phase 3
Recruiting
2024/02/01
Not Applicable
Completed
Fahad Javed Awan
2023/06/28
Phase 3
Recruiting
2022/12/01
Phase 3
Withdrawn
2022/09/16
Phase 2
Active, not recruiting
2022/07/20
Phase 3
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Healthlife of USA
69517-133
ORAL
65 mg in 1 1
12/20/2017
Uriel Pharmacy, Inc.
48951-4197
ORAL
1 [hp_X] in 1 1
8/1/2025
Carwin Pharmaceutical Associates, LLC
15370-102
ORAL
9.5 mg in 1 mL
4/21/2017
Pangea Pharmaceuticals, LLC
81279-101
ORAL
9.5 mg in 1 mL
12/22/2023
PD-Rx Pharmaceuticals, Inc.
72789-436
ORAL
65 mg in 1 1
5/7/2025
Method Pharmaceuticals, LLC
58657-327
ORAL
10 mg in 1 mL
12/12/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
FERINSOL DROPS
mead johnson nutritionals
00017841
Drops - Oral
125 MG / ML
12/31/1951
FERROUS SULFATE TABLETS 300MG
pharmadex laboratories inc.
01987135
Tablet - Oral
300 MG
12/31/1993
LIVRON PLUS AMPOULE
medic laboratory ltée
00520004
Liquid - Oral
36 MG / 10 ML
12/31/1980
ARCHANGELICA COMP. PELLETS
02232700
Pellet - Oral
2 D
4/10/1998
PILULES DUCASE
produits francais labs inc.
00166359
Tablet - Oral
5 MG
12/31/1930
NOVO-FERROSULFA TAB 300MG(FCT)
novopharm limited
00021962
Tablet - Oral
300 MG
12/31/1991
FERROUS SULFATE ECT 300MG
bionatal drug co
00332747
Tablet (Enteric-Coated) - Oral
300 MG
12/31/1977
FERRUM SULFURICUM-INJEEL LIQ (10D,30D,200D/1.1ML)
02063107
Liquid - Oral
10 D / 1.1 ML
12/31/1994
HOMEOPATHIC MEDICINE (S#755) DPS 30C
total health centre
02081121
Drops - Oral
30 C / ML
12/31/1994
FERROUS SULFATE TAB 325MG USP
00722413
Tablet - Oral
325 MG
12/31/1991

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.